AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients
Amgen's Repatha was found to be more effective in reducing follow-up cardiovascular events in high-risk heart attack patients. (Amgen)
PHILADELPHIA—With new competition potentially on its way in the PCSK9 inhibitor class, Amgen's stalwart Repatha is looking for a leg up in treating high-risk heart attack patients.
A new analysis shows that patients within the one-year mark of a heart attack are at a much higher risk of a following cardiovascular event––and cholesterol-lowering Repatha is particularly effective in treating that group.
Patients treated with a Repatha-statin combo within one year after a heart attack showed a 25% risk reduction in follow-up CV events, including heart attack, death or stroke, over statins alone. In patients treated with the combo after the one-year mark, there was a reported 15% risk reduction, according to an analysis of data from Amgen's Fourier outcomes trial set to be presented Monday at the American Heart Association's Scientific Sessions.
Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D
Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.
Chris Kurtz, Amgen's vice president and global development and therapeutic area head for cardiovascular and metabolic, reinforced Repatha's clinical effect on high-risk heart attack patients by intensively lowering LDL-C levels.
"It’s good that we have validation, but it's maybe not a surprising result," Kurtz said. "I would say there’s a growing body of evidence that there’s urgency around risk-factor control and LDL reduction, and now we have tools to do it."